Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
Thursday, December 12 2024 | 13 h 03 min | News
Bausch + Lomb Corporation announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants and bolsters Bausch + Lomb’s glaucoma portfolio, which features pharmaceutical and surgical approaches.
“Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040.”1
Compared to other glaucoma surgery techniques, MIGS offers a safe and effective approach to lowering intraocular pressure with faster recovery time.2 It can also often be performed in conjunction with cataract surgery, the most routinely performed surgery in the world.3 More than 19% of patients who need cataract surgery also have glaucoma or ocular hypertension4; cataract surgery provides an optimal opportunity for concurrent glaucoma treatment.
“ELIOS provides a tissue-friendly, precision non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma. The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patient quality of life.”
Professor Ike K. Ahmed, MD, University of Toronto and Moran Eye Center
“Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help change the treatment paradigm for the estimated 80 million people worldwide living with glaucoma,” said Elliot Friedman, former Elios Vision chairman and CEO. “The goal is to make combining cataract and glaucoma treatment the new standard of care, and that’s even more attainable given Bausch + Lomb’s presence in nearly 100 countries.”
The ELIOS technology, which is CE marked, is currently marketed and sold in the European Union. Elios Vision is in the process of pursuing U.S. Food and Drug Administration approval for the product.
Click here for a video demonstration of how ELIOS works.
Leerink Partners served as exclusive financial advisor to Elios Vision and Wilson Sonsini Goodrich & Rosati, Professional Corporation served as legal advisor.
Source: Bausch + Lomb
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
